Center for Evidence Based Chinese Medicine, Institute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences, Beijing 100700, China.
Department of Encephalopathy, Chongqing Hospital of Traditional Chinese Medicine, Chongqing 400021, China.
J Tradit Chin Med. 2023 Oct;43(6):1259-1267. doi: 10.19852/j.cnki.jtcm.20221006.004.
This study is to investigate the effectiveness and safety of bloodletting puncture (BP) for acute ischemic stroke (AIS) when used in combination with standard treatment, as well as the patients' feelings and attitudes toward the treatment. This is a mixed method research which includes a multi-center, superiority, randomized controlled clinical trial, and focus group interview. A total of 360 AIS participants will be enrolled. They will be randomized into one of the following two groups for 7 d: (a) BP with standard treatment group ( 180); (b) standard treatment group ( 180). The primary outcome will be National Institute of Health stroke scale (NIHSS) score at day 7 after treatment. Secondary outcomes will be changes of Glasgow Coma Scale score, NIHSS score, mRS and Traditional Chinese Medicine syndrome score from baseline to 7, 14, and 30 d after treatment, recurrence rate and all-cause mortality rate within 30 d, and the safety assessments. The focus group will be conducted with a purposive sample of 1-2 acupuncturists and 1-2 patients respectively at each center at 7 and 30 d after treatment. We designed a mixed method study to evaluate the effect of BP, an acupuncture therapy for patients with AIS. If the findings of this study confirm the effectiveness of BP to reduce the NIHSS score and other related outcomes and patients are willing to accept the therapy, we believe this study will help the implementation of this therapy in clinical practice, and provide new evidence for the treatment of AIS.
本研究旨在探讨刺血疗法(BP)联合标准治疗急性缺血性脑卒中(AIS)的有效性和安全性,以及患者对治疗的感受和态度。这是一项混合方法研究,包括一项多中心、优效性、随机对照临床试验和焦点小组访谈。将纳入 360 名 AIS 患者,随机分为以下两组,进行 7d 的治疗:(a)BP 联合标准治疗组(180 例);(b)标准治疗组(180 例)。主要结局指标为治疗后第 7 天的国立卫生研究院卒中量表(NIHSS)评分。次要结局指标为治疗后第 7、14、30d 的格拉斯哥昏迷量表评分、NIHSS 评分、mRS 和中医证候评分的变化,治疗后 30d 内的复发率和全因死亡率,以及安全性评估。在治疗后第 7 和 30d,在每个中心,我们将采用目的抽样方法分别对 1-2 名针灸师和 1-2 名患者进行焦点小组访谈。我们设计了一项混合方法研究来评估 BP 对降低 NIHSS 评分和其他相关结局的效果,以及患者对治疗的接受程度。如果这项研究的结果证实 BP 可以降低 NIHSS 评分和其他相关结局,且患者愿意接受这种治疗,我们相信这项研究将有助于该疗法在临床实践中的实施,并为 AIS 的治疗提供新的证据。